Regulation of endothelial VCAM-1 expression in murine cardiac grafts: Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-α or IL-4 and is not required for allograft rejection

S. D. Bergese, E. H. Huang, R. P. Pelletier, M. B. Widmer, R. M. Ferguson, C. G. Orosz

Research output: Contribution to journalArticlepeer-review

Abstract

This report provides evidence to support the hypothesis that tumor necrosis factor-α (TNF-α) and IL-4 promote the expression of new endothelial surface molecules in rejecting murine heterotopic cardiac allografts. The microvascular endothelia of these cardiac allografts all develop strong reactivity, with the monoclonal antibodies (mAbs) YN1.1/74 (anti-ICAM-1), M/K-2 (anti-VCAM-1) and MECA-32 (undefined molecule) within 3 to 5 days of graft implantation. Daily treatment of the allograft recipients with pentoxifylline (PTX), soluble TNF receptor (TNFR:Fc), anti-interleukin- 4 (IL-4) mAb (11B11), or soluble IL-4 receptor, each abrogate the expression of endothelial VCAM-1 and reduce the endothelial reactivity with the mAbs YN1.1/74 and MECA-32 to levels found in cardiac isografts. This is accompanied by a reduction, but not an elimination, of interstitial leukocytic infiltration. Despite this, cardiac allograft recipients treated with PTX or the mAb 11B11 rejected allografts at the same rate as untreated allograft recipients, ie, within 10 to 12 days after graft implantation. These rejected grafts contained mRNAs for TNF-α and IL-4, as well as for all other cytokines that have been associated with rejecting allografts. This suggests that endothelial VCAM-1 expression, which is characteristic of rejection, is not an essential element of the rejection process. Interestingly, the grafts from the PTX-treated recipients continued to display rare, isolated VCAM-1 possible cells in the interstitium, which may be dendritic cells. In general, these studies demonstrate a role for IL-4 and TNF-α in the alterations of vascular endothelial phenotype observed in rejecting cardiac allografts. They also demonstrate that endothelial VCAM-1 expression is not essential for the allograft rejection process, and that the role of VCAM-1 in this process may be more subtle than was initially suspected.

Original languageEnglish (US)
Pages (from-to)166-175
Number of pages10
JournalAmerican Journal of Pathology
Volume147
Issue number1
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'Regulation of endothelial VCAM-1 expression in murine cardiac grafts: Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-α or IL-4 and is not required for allograft rejection'. Together they form a unique fingerprint.

Cite this